Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

被引：0
|
作者：
Sinclair, Rodney [1 ]
Thaci, Diamant [2 ]
Vender, Ronald [3 ]
de Rie, Menno [4 ]
Conrad, Curdin [5 ]
Soung, Jennifer [6 ]
Strober, Bruce [7 ,8 ]
Wang, Maggie [9 ]
Cross, Nancy [10 ]
Deherder, Delphine [9 ]
Gomez, Natalie Nunez [11 ]
Gottlieb, Alice B. [12 ]
机构：
[1] Sinclair Dermatol, East Melbourne, Vic, Australia
[2] Univ Lubeck, Lubeck, Germany
[3] Dermatrials Res Inc, Hamilton, ON, Canada
[4] Univ Amsterdam, Dept Dermatol, Med Ctr, Amsterdam, Netherlands
[5] Lausanne Univ Hosp, Dept Dermatol, Lausanne, Switzerland
[6] Southern Calif Dermatol, Santa Ana, CA USA
[7] Yale Univ, New Haven, CT USA
[8] Cent Connecticut Dermatol Res, Cromwell, CT USA
[9] UCB Pharma, Brussels, Belgium
[10] UCB, Morrisville, NC USA
[11] UCB Pharma, Monheim, Germany
[12] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
    Ferrante, Marc
    Panaccione, Remo
    Colombel, Jean Frederic
    Dubinsky, Marla C.
    Hisamatsu, Tadakazu
    Lindsay, James O.
    Song, Alexandra P.
    Neimark, Ezequiel
    Zhang, Ying
    Kligys, Kristina
    Crowley, Jameson
    Duan, W. Rachel
    D'Haens, Geert
    GASTROENTEROLOGY, 2024, 166 (05) : S801 - S802
  • [32] Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial
    Buynak, Robert
    Rappaport, Stephen A.
    Rod, Kevin
    Arsenault, Pierre
    Heisig, Fabian
    Rauschkolb, Christine
    Etropolski, Mila
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2420 - 2438
  • [33] Long-term safety and efficacy of risankizumab for the treatment of moderate- to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
    Papp, Kim A.
    Blauvelt, Andrew
    Puig, Lluis
    Ohtsuki, Mamitaro
    Beissert, Stefan
    Gooderham, Melinda
    Amin, Ahmad Z.
    Liu, Jie
    Wu, Tianshuang
    Azam, Tofial
    Stakias, Vassilis
    Espaillat, Ramon
    Sinvhal, Ranjeeta
    Soliman, Ahmed M.
    Pang, Yinuo
    Chen, Michael M.
    Lebwohl, Mark G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (06) : 1149 - 1158
  • [34] Long-term safety and efficacy of ABT-874 for the treatment of moderate to severe psoriasis: Interim analysis from an open-label extension study
    Langley, Richard
    Valdes, Joaquin
    Gordon, Kenneth
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB148 - AB148
  • [35] Efficacy and safety of briakinumab for treatment of moderate to severe psoriasis in patients previously receiving etanercept: Results from an open-label extension
    Strober, Bruce
    Leonardi, Craig
    Williams, David A.
    Olds, Michele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB191 - AB191
  • [36] Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
    Wechsler, Michael E.
    Ford, Linda B.
    Maspero, Jorge F.
    Pavord, Ian D.
    Papi, Alberto
    Bourdin, Arnaud
    Watz, Henrik
    Castro, Mario
    Nenasheva, Natalia M.
    Tohda, Yuji
    Langton, David
    Cardona, Guido
    Domingo, Christian
    Park, Hae Sim
    Chapman, Kenneth R.
    Mao, Xuezhou
    Zhang, Yi
    Khan, Asif H.
    Deniz, Yamo
    Rowe, Paul J.
    Kapoor, Upender
    Khokhar, Faisal A.
    Mannent, Leda P.
    Ruddy, Marcella
    Laws, Elizabeth
    Amin, Nikhil
    Hardin, Megan
    LANCET RESPIRATORY MEDICINE, 2022, 10 (01): : 11 - 25
  • [37] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
    Papp, Kim
    Leonardi, Craig
    Gordon, Kenneth
    Frevert, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
  • [38] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [39] 416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [40] BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
    Merola, J. F.
    Gottlieb, A. B.
    Morita, A.
    Carrascosa, J. M.
    Elewski, B.
    Tilt, N.
    Wiegratz, S.
    Wixted, K.
    Mrowietz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1766 - 1767
12345